ClinicalTrials.gg
Not yet recruitingNCT07713862MELOWUpdated Jul 23, 2026

Midlife Empowerment and Longevity Through Optimizing Wellness

An interventional study of MELOW in Menopause, sponsored by National University Health System, Singapore. Not yet recruiting. Open to female participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by National University Health System, Singapore · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
Female
01

Study summary

The goal of this observational longitudinal study is to understand how lifestyle behaviours, menopausal symptoms, and digital health data change over time in women experiencing perimenopause or menopause, and to evaluate whether a personalised digital health programme can support healthier lifestyle behaviours and improve cardiometabolic health.

The main questions it aims to answer are:

  1. Can personalised lifestyle recommendations informed by wearable devices, dietary logging, and self-reported symptoms improve adherence to healthy diet, physical activity, and sleep behaviours?
  2. How are menopausal symptoms associated with changes in cardiometabolic health, body composition, physical function, and quality of life over time?

Participants will:

  1. Attend study visits at the National University of Singapore for health assessments, including measurements of body composition, physical function, and cardiometabolic health.
  2. Wear a smartwatch or wearable device to monitor physiological and activity data throughout the study.
  3. Use a mobile application to record dietary intake, menopausal symptoms, and other health-related information.
  4. Receive personalised lifestyle recommendations based on their health data and engage in regular follow-up assessments over the study period.
Read the detailed description

The Midlife Empowerment and Longevity through Optimizing Wellness (MELOW) study is a 12-month, two-arm, parallel-group, stratified randomized controlled trial designed to evaluate the effectiveness of a personalized digital lifestyle intervention for improving menopausal symptoms, lifestyle behaviours, and cardiometabolic health among perimenopausal women.

The primary objective of the study is to determine whether a personalized digital lifestyle intervention improves menopausal symptoms and cardiometabolic health. Secondary objectives include evaluating changes in body composition, physical function, glucose regulation, cardiovascular risk markers, gut microbiome composition, lifestyle behaviours, sleep, psychological well-being, and health-related quality of life. The study will also evaluate participant engagement with the digital intervention and explore relationships between wearable-derived physiological data, behavioural patterns, and menopausal symptom trajectories over time.

Following eligibility screening and informed consent, participants will attend a baseline assessment at the National University of Singapore (NUS). Baseline assessments include collection of demographic information, medical history, medication use, lifestyle behaviours, and menopausal history. Participants will undergo comprehensive cardiometabolic assessments, including waist circumference, blood pressure, heart rate, body composition analysis, handgrip strength, physical function assessed using the Short Physical Performance Battery (SPPB), and cognitive function assessed using the Montreal Cognitive Assessment (MoCA). Fasting venous blood samples will be collected for the measurement of cardiometabolic biomarkers, including glucose and lipid profiles, and stool samples will be collected for gut microbiome analyses. Participants will also complete validated questionnaires assessing menopausal symptoms, dietary behaviours, physical activity, mood, anxiety, stress, sleep, eating behaviours, and health-related quality of life.

All participants will receive standardized educational materials on healthy lifestyle behaviours and menopause management. Participants will also be provided with a continuous glucose monitor (CGM) for 15 days and an Oura Ring to collect continuous physiological and behavioural data, including sleep, physical activity, heart rate, and glucose responses.

Following completion of baseline assessments, participants will be randomly assigned using stratified randomization in a 1:1 ratio to either the MELOW intervention group or the control group.

Participants assigned to the intervention group will receive access to the MELOW mobile application for 6 months. During onboarding, participants will complete a goal-setting exercise to establish personalized health goals and behavioural targets. Throughout the intervention period, participants will complete brief ecological momentary assessments (EMAs) at least three times daily to report current symptoms, mood, energy levels, appetite, and other health-related states. These participant-reported data will be integrated with data collected from the wearable devices to generate personalized just-in-time adaptive interventions (JITAIs), including tailored behavioural recommendations and supportive messages designed to promote healthy eating, physical activity, sleep, and symptom self-management. Participants will also have access to an individualized dashboard displaying longitudinal trends in behavioural, physiological, and symptom data. Automated reminders will be delivered if scheduled app check-ins are missed.

Participants assigned to the control group will not receive access to the MELOW mobile application or personalized digital intervention during the study period. They will continue to receive standard educational materials provided at baseline and will complete the same assessment schedule as the intervention group.

All participants will attend follow-up visits at 6 and 12 months after enrolment. Follow-up assessments will repeat the baseline cardiometabolic measurements, body composition analysis, physical function assessments, fasting blood collection, stool sample collection, and questionnaire administration to evaluate longitudinal changes in health outcomes.

With participants' separate consent, any remaining biological samples and de-identified study data may be stored for future research related to metabolic health, diabetes, cardiometabolic disease, menopause, and lifestyle interventions. All data and biological specimens will be managed in accordance with institutional policies and applicable data protection regulations. Clinically significant incidental findings identified during study assessments may be communicated to participants with advice to seek appropriate medical follow-up.

02

Conditions studied

  • Menopause
03

In context

Lead sponsor

National University Health System, Singapore is the lead sponsor of 42 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 21-65 years old;
  • Report at least mild climacteric symptoms as indicated by an MRS score ≥5;
  • Waist circumference ≥80 cm, indicating abdominal adiposity;
  • Own and use a smartphone compatible with the CGM and Oura Ring.

Exclusion criteria

Exclusion Criteria:

  • Are currently receiving hormone replacement therapy (HRT);
  • Are currently using oral ;
  • Have been diagnosed with severe psychiatric illness requiring inpatient care;
  • Are concurrently enrolled in another behavioural or psychotherapy trial;
  • Have significant cognitive impairment or inability to engage with digital tools;
  • Have uncontrolled chronic medical conditions that may interfere with study participation;
  • Unable to comprehend written and spoken English.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • No intervention
    Control

    Participants in the control group will not have access to the MELOW app during the study period

  • Experimental
    MELOW

    Participants will be required to download and set up an app on your smartphone and complete a short health goal-setting exercise. They will be asked to respond to brief check-in questions through the app at least three times a day regarding energy levels, mood, appetite, and any symptoms such as hot flushes or sleep difficulties. Participant will then receive short personalised messages through the app based on wearables data and responses to support in managing symptoms and maintaining healthy habits. The app will send reminders if it receives no response to the prompts. They will also be able to view a personalised health dashboard on the app, updated regularly as device data syncs.

    Behavioral: MELOW

Interventions

  • BehavioralMELOW

    Participants will be required to download and set up an app on your smartphone and complete a short health goal-setting exercise. They will be asked to respond to brief check-in questions through the app at least three times a day regarding energy levels, mood, appetite, and any symptoms such as hot flushes or sleep difficulties. Participant will then receive short personalised messages through the app based on wearables data and responses to support in managing symptoms and maintaining healthy habits. The app will send reminders if it receives no response to the prompts. They will also be able to view a personalised health dashboard on the app, updated regularly as device data syncs.

06

What researchers measure

Primary outcomes

  1. Change in Menopause Rating Scale (MRS)

    Menopause Rating Scale (MRS) is an 11-item questionnaire used to measure the severity of menopausal symptoms and the impact on quality of life. It evaluates 11 symptoms on a 0 to 4 scale, whereby 0 is 'No symptoms', 1 is 'Mild' 2 is 'Moderate', 3 is 'Severe', and 4 is 'Extremely severe'. The MRS score with a minimum score of 0 and maximum score of 44. The higher the score, the more severe the menopause symptoms.

    Time frame: Change in Menopause Rating Scale (MRS) score from enrolment to 6 month mark

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2030
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07713862
Lead sponsor
National University Health System, Singapore
Responsible party
Jocelyn Chew (Assistant Professor, Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore (NUS), National University Health System, Singapore) — Principal investigator
First posted
Jul 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Jul 23, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion